Evidence map›Paper›PMID 40133263›Full record

ArticleNature communications2025

Zika but not Dengue virus infection limits NF-κB activity in human monocyte-derived dendritic cells and suppresses their ability to activate T cells.

Ying-Ting Wang, Emilie Branche, Jialei Xie, Rachel E McMillan, Fernanda Ana-Sosa-Batiz, Hsueh-Han Lu, Qin Hui Li, Alex E Clark, Joan M Valls Cuevas, Karla M Viramontes and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Oral lipid prodrug V2043 (1-Antimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ying-Ting WangCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Emilie BrancheCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Jialei XieDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Rachel E McMillanDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Fernanda Ana-Sosa-BatizCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Hsueh-Han LuCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0832-9607
Qin Hui LiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-2792-9018
Alex E ClarkDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1687-416X
Joan M Valls CuevasCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Karla M ViramontesCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Aaron F GarretsonDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3855-4482
Rúbens Prince Dos Santos AlvesCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-5538-6025
Sven HeinzDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4665-1007
Christopher BennerDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Aaron F CarlinDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA. acarlin@health.ucsd.edu.ORCID http://orcid.org/0000-0002-1669-8066
Sujan ShrestaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA. sujan@lji.org.ORCID http://orcid.org/0000-0003-2906-8474

Funding

Development of a Replicon RNA-based Vaccine against Dengue and ZikaR01AI163188 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SHRESTA, SUJAN · 2021 to 2025
$3.6M
Maternal Antibody-Mediated Enhancement of Dengue PathogenesisR01AI153500 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SHRESTA, SUJAN · 2021 to 2025
$3.1M
UC San Diego Genetics Training ProgramT32GM145427 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRUCE A HAMILTON · 2022 to 2026
$2.6M
IRF-3/5/7-Independent Antiviral ImmunityR01AI116813 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SHRESTA, SUJAN · 2016 to 2019
$1.9M
Multiscale genomic decryption of regulatory DNAR35GM149520 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Christopher W Benner · 2024 to 2026
$1.2M
Deconvolution of pro- and anti-viral responses to Dengue virus and Zika Virus infectionsK08AI130381 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARLIN, AARON F. · 2019 to 2023
$1.0M
Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) 108-2917-I-564-032NIAID NIH HHS K08 AI130381NIAID NIH HHS R01 AI116813NIAID NIH HHS R01 AI153500NIAID NIH HHS R01 AI163188NIGMS NIH HHS R35 GM149520NIGMS NIH HHS T32 GM145427
6 · The paper itself

Abstract

Understanding flavivirus immunity is critical for the development of pan-flavivirus vaccines. Dendritic cells (DC) coordinate antiviral innate and adaptive immune responses, and they can be targeted by flaviviruses as a mechanism of immune evasion. Using an unbiased genome-wide approach designed to specifically identify flavivirus-modulated pathways, we found that, while dengue virus (DENV) robustly activates DCs, Zika virus (ZIKV) causes minimal activation of genes involved in DC activation, maturation, and antigen presentation, reducing cytokine secretion and the stimulation of allogeneic and peptide-specific T cell responses. Mechanistically, ZIKV inhibits DC maturation by suppressing NF-κB p65 recruitment and the subsequent transcription of proinflammatory and DC maturation-related genes. Thus, we identify a divergence in the effects of ZIKV and DENV on the host T cell response, highlighting the need to factor such differences into the design of anti-flavivirus vaccines.

Indexed as

Dendritic CellsDengueDengue VirusLymphocyte ActivationNF-kappa BT-LymphocytesZika VirusZika Virus InfectionAntigen PresentationCytokinesHumansMonocytesCytokinesNF-kappa B

Identifiers

PMID40133263
PMCPMC11937581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.